In the Phase Ib JADE trial, OLN324 demonstrated both faster and greater retinal drying versus Vabysmo in patients with DME, ...

NRG Therapeutics has dosed the first participants in its Phase I clinical trial of NRG5051, being developed as a ...

GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.

In the ongoing study (NCT06700538), Arrowhead’s candidate, called ARO-INHBE, plus Zepbound, doubled weight loss and tripled ...

Treatment with the tumour necrosis factor receptor 2 (TNFR2)-targeting monoclonal antibody (mAb) plus Keytruda was also found ...

Neumora Therapeutics’ oral Alzheimer’s disease agitation drug has shown benefit, reducing agitation, in a Phase Ib trial.

While obexelimab failed to best Uplizna in terms of efficacy, Zenas will still file for the drug’s approval in IgG4-RD.

MetaVia will now be investigating the candidate at two different titration levels in 16-week trials for obesity.

The PRISM process analyses electronic health records, medical histories, diagnoses, and clinical characteristics to determine patient trial eligibility. Credit: Mount Sinai. The Mount Sinai Tisch ...

The decision to end the trial was based on an interim analysis that showed a numerically lower favourable response rate and a numerically higher mortality rate in the opelconazole arm. Image credit: ...

MSD aims to enrol around 675 patients worldwide. Credit: Jo Panuwat D / Shutterstock.com. Merck & Co (MSD) has commenced the KANDLELIT-007 Phase III trial to assess calderasib (MK-1084), with Keytruda ...

Patients reported clinically meaningful improvements in quality of life and itch. Credit: Hriana / Shutterstock.com. Alumis has announced positive top line data from its Phase III ONWARD1 and ONWARD2 ...